| PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. | thyroid, |
| Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. | thyroid, |
| Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. | thyroid, |
| The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. | thyroid, |
| PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. | neoplasm, |
| The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis. | thyroid, |
| The Role of the PAX8/PPARgamma Fusion Oncogene in Thyroid Cancer. | thyroid, |
| The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. | thyroid, |
| PAX8-PPARgamma oncogene in follicular thyroid tumors: RT-PCR and immunohistochemical analyses. | thyroid, |
| hese findings provide mechanistic and therapeutic insights for PAX8-addicted ovarian cancer. More generally, our analytic and experimental approach represents an expandible paradigm for identifying and targeting lineage-survival oncogenes in diverse human malignancies. | ovarian, |
| The data identifies PAX8 as a candidate oncogene in Renal Cell Carcinoma and provides a potential biomarker to monitor its activity. | kidney, |
| The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition. | None |
| An unusual negative cross talk between Ras oncogene and the cyclic AMP pathway induces inactivation of the transcription factor Pax8. | None |
| The Putative PAX8/PPARgamma Fusion Oncoprotein Exhibits Partial Tumor Suppressor Activity through Up-Regulation of Micro-RNA-122 and Dominant-Negative PPARgamma Activity. | None |